Your urologist will use several tests to determine how severe your BPH is and whether it affects your bladder health. They may recommend watchful waiting if your BPH is mild. Watchful waiting means ...
A regulatory decision is expected in the third quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for vibegron for the treatment of men ...
WAYNE, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced results of a new survey showing that the majority of American men over age 40 are prescribed multiple ...
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
Medical Device Network on MSN
FDA clears Francis Medical’s water vapour ablation treatment for prostate cancer
The Vanquish device’s clinical data demonstrated an elimination of MRI visible intermediate risk disease in 91% of patients ...
Investor's Business Daily on MSN
Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'?
Janux Therapeutics stock crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer ...
Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of prostate cancer, today announced that the U.S.
Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute myeloid leukemia (AML), according to a new study by researchers at.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback